Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Shire Rises As US FDA Approves Takhzyro Drug

Fri, 24th Aug 2018 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Shire, up 2.6%. The Irish pharmaceutical company said the US Food & Drug Administration has approved its Takhzyro drug to treat a rare genetic disease. The disease, hereditary angioedema, causes attacks of swelling in different parts of the body and can be life-threatening. Approval from the FDA follows a phase III study of 125 patients in which Takhzyro reduced monthly attacks by, on average, 87% in patients when compared with a placebo. Antofagasta, up 2.0%. RBC Capital upgraded the Chilean copper miner to Outperform from Sector Perform. ----------FTSE 100 - LOSERS----------Berkeley Group, down 2.3%, Barratt Developments, down 1.9%, Persimmon, down 1.7%, Taylor Wimpey, down 1.2%. The housebuilders were lower amid a decline in UK mortgage approvals in July. The number of mortgages approved in July fell to 39,584 from 40,330 in June. Economists had forecast approvals to rise to 40,650, data from UK Finance showed. "Housebuilders have taken a knock as a double whammy of lower new approved mortgages and a five-month low in mortgage lending weighed on the sector," IG Group analyst Chris Beauchamp said. Midcap peers McCarthy & Stone, Bovis Homes and Bellway were down 2.1%, 1.4% and 1.2%, respectively. ----------FTSE 250 - WINNERS----------Ted Baker, up 2.0%. Peel Hunt raised the high street fashion retailer to Add from Hold. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Henry Boot, up 4.5%. The construction company said interim profit and revenue both rose in an "impressive" first half performance. For the six months to June, Henry Boot's pretax profit was up 16% to GBP26.2 million, while revenue rose slightly to GBP196.2 million from GBP195.4 million a year prior. Its net asset value per share increased by 18% to 217 pence. Henry Boot is paying an interim dividend to shareholders of 3.20p, from 2.80p a year prior. The company said it has seen "consistent" levels of demand across all of its businesses in the first half of 2018, particularly in housing development land. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Bahamas Petroleum, down 63%. The oil and gas explorer said its exclusivity agreement with a major international oil company will terminate at the end of the month. The unnamed international company has notified Bahamas that it will not be extending the agreement, which has been in place since the start of May, past next Friday and will cease exclusivity payments. Bahamas said it has recommenced broader asset-based discussions with third parties. These will continue alongside the ongoing non asset-based discussions which surround the funding of its first exploration well.----------
More News
25 Oct 2018 15:20

TOP NEWS: Shire Seeks US Approval To Make Flexbumin At New Facility

LONDON (Alliance News) - Pharmaceutical company Shire PLC on Thursday said it has filed a submission to the US Food & Drug Administration for approval to manufacture Flexbumin at its new is as

Read more
23 Oct 2018 16:25

MOVES-JPMorgan reshuffles healthcare group, co-head departs -sources

By Greg Roumeliotis and Liana B. Baker Oct 23 (Reuters) - JPMorgan Chase & Co has appointed Mike Gaito as global co-head of healthcare investment banking after Jeff Stute, who held that

Read more
19 Oct 2018 14:38

Shire's lanadelumab gets one step closer to European approval

(Sharecast News) - Rare disease-focussed biotechnology company Shire announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorisation of 'lanadelumab' injection, for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Read more
18 Oct 2018 09:26

UPDATE 1-Takeda gets Japanese approval for $62 bln Shire purchase

Oct 18 (Reuters) - Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to a it

Read more
1 Oct 2018 11:24

Schroder Japan Growth Outperforms Benchmark In Full Year

LONDON (Alliance News) - Schroder Japan Growth Fund PLC said on Monday it outperformed its benchmark in its recently ended financial year due to a robust performance in the first half, in spite of

Read more
28 Sep 2018 06:23

UK Stocks-Factors to watch on Sept 28

Sept 28 (Reuters) - Britain's FTSE 100 index is seen opening 8 points higher at 7,553 on Friday, according to financial bookmakers. * SHIRE: Japan M&A volumes are set to break a 19-year-old

Read more
28 Sep 2018 04:09

Morning News Call - India, September 28

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_09282018.pdf If you would like to receive this newsletter via email, please at: TO

Read more
27 Sep 2018 17:53

UPDATE 1-FTSE rises to 4-week high helped by sterling weakness

* FTSE 100 up 0.5 pct * Higher crude lifts oil stocks, hits airlines * TUI sticks to forecasts, shares gain (Adds details, closing prices) By Danilo Masoni MILAN, Sept

Read more
21 Sep 2018 11:26

Shire Gets Japanese Approval For Rare Genetic Disease Drug Firazyr

LONDON (Alliance News) - Pharmaceutical company Shire PLC on Friday said it has been granted manufacturing and marketing authorisation in Japan for its hereditary angioedema drug, Japanese of has

Read more
21 Sep 2018 07:19

Shire gets approval for hereditary angioedema treatment in Japan

(Sharecast News) - Rare disease specialist Shire announced on Friday that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for its 'FIRAZYR' icatibant injection, for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE.

Read more
17 Sep 2018 06:41

UK Stocks-Factors to watch on Sept 17

Britain's FTSE 100 index is seen opening 11 points lower at 7,293 on Monday, according to financial bookmakers. * GOLD: Gold inched up on Monday as bargain-hunters bought the metal after prices

Read more
14 Sep 2018 17:28

UPDATE 1-FTSE tracks Europe higher; Shire shines

* FTSE 100 up 0.3 pct * Shire gains after China nod to Takeda deal * Housebuilders in focus * Investec rallies on spin-off plans (Adds closing) By Danilo Sept 14 - top

Read more
14 Sep 2018 12:01

LONDON MARKET MIDDAY: Stocks Higher As Shire And Whitbread Gain

LONDON (Alliance News) - Stocks in London were higher at midday on Friday with Shire and Whitbread performing well among FTSE 100 constituents, while in the FTSE was

Read more
14 Sep 2018 10:32

WINNERS & LOSERS SUMMARY: Housebuilders Hit By No-Deal Brexit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 1.8%. Takeda Pharmaceutical said it had in of

Read more
14 Sep 2018 10:16

FTSE tracks Europe higher on trade hopes; Shire shines

(For a live blog on European stocks, type LIVE/ in an Eikon news window) * FTSE 100 up 0.1 pct * Shire gains after China nod to Takeda deal * Housebuilders under Investec on -

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.